An international phase III multicenter, double-blind, randomized clinical trial compared twice-daily LPV/RTV 400/100 mg with three-times-daily nelfinavir (NFV) 750 mg, both in combination with Stavudine generic (d4T) and Lamivudine generic (3TC). The study consisted of 653 patients without prior antiretroviral therapy experience, 129 of whom were women. Baseline characteristics consisted of a mean HIV RNA [...]
In terms of antiviral activity, PIs inhibit the HIV protease enzyme, which is required for the proteolytic cleavage of viral polyprotein precursors. PIs bind to the active site on the HIV-1 protease enzyme and prevent the processing of viral GaG and GaG-pol polyprotein precursors. This results in the formation of immature, noninfectious viral particles.
Nevirapine, Delavirdine, and Efavirenz drug The first NNRTI, nevirapine (NVP) (Viramune®, Boehringer Ingelheim), was approved in June 1996. Delavirdine (DLV) (Rescriptor®, Pharmacia & Upjohn) received approval in April 1997, and EFV was approved in September 1998. Studies with NNRTIs, in particular with EFV, have received considerable attention. NVP has been extensively studied in resource-poor countries [...]
Tenofovir On October 26, 2001, tenofovir (Viread®, Gilead Sciences) became the first FDA-approved agent in the NtRTI class. The drug was the second of two agents in this class to be developed by Gilead. Adefovir dipivoxil, the other agent in this class then under investigation, is no longer under consideration as an anti-HIV agent following [...]
The history of antiretroviral agents that have been approved by the Food and Drug Administration (FDA) dates from March 19, 1987, when generic zidovudine (ZDV), also known as AZT (Retrovir canadian, GlaxoSmithKline), became the first drug to be used to treat patients with acquired immunodeficiency syndrome (AIDS). Since that time, the therapy for patients with [...]
The resistance of bacteria to antibiotics tablet, particularly those used for first-line therapy, is an increasing cause for concern. The continued surveillance of hospital bacteria and their resistance pattern is important in the management of nosocomial infections.
Overall Pattern A total of 1,718 isolates were studied. Coliforms comprised 897 (52.2% of) isolates and showed high percentage sensitivity to ceftazidime (86.47%), pefloxacine (83.7%) and drug ciprofloxacin (89.7%), with much reduced sensitivity to generic ampicillin (19.1%) and tablet cotrimoxazole (11.1%) (Figure 1). S. aureus was most sensitive to ciprofloxacin (96.2%), pefloxacine (90.7%>) and cephalexin [...]
